| William Samuel Einhorn, MD | |
|
593 Eddy St, Providence, RI 02903-4923 | |
| (401) 444-5184 | |
| (401) 444-5017 |
| Full Name | William Samuel Einhorn |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 10 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295149565 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore Medical Center - | Salem, MA | Hospital |
| Wentworth-douglass Hospital | Dover, NH | Hospital |
| Cooley Dickinson Hospital Inc,the | Northampton, MA | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harbor Medical Associates Inc | 2466356209 | 237 |
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
| Cd Practice Associates Inc | 2567359839 | 304 |
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
| Rhode Island Medical Imaging | 8022097815 | 108 |
| Cooley Dickinson Hospital Inc | 8123090560 | 37 |
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
| Rhode Island Medical Imaging | 8022097815 | 108 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Cd Practice Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295787919 PECOS PAC ID: 2567359839 Enrollment ID: O20040302000290 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Harbor Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124079561 PECOS PAC ID: 2466356209 Enrollment ID: O20040719000954 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Cooley Dickinson Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477596310 PECOS PAC ID: 8123090560 Enrollment ID: O20040806001098 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Commonwealth Radiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295711661 PECOS PAC ID: 2668468406 Enrollment ID: O20081210000048 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Merrimack Radiology-cra Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275871154 PECOS PAC ID: 8426287269 Enrollment ID: O20140128000095 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Entity Name | Rhode Island Medical Imaging |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942376033 PECOS PAC ID: 8022097815 Enrollment ID: O20180523000302 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Samuel Einhorn, MD 125 Metro Center Blvd Ste 2000, Warwick, RI 02886-1785 Ph: (401) 432-2500 | William Samuel Einhorn, MD 593 Eddy St, Providence, RI 02903-4923 Ph: (401) 444-5184 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
In his latest column, James Capretta writes: "When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process.
Allscripts announced today that Mountain States Health Alliance (MSHA) has selected the Allscripts Electronic Health Record (EHR) and Practice Management (PM) solutions for 300 employed and affiliated physicians and mid-level providers to enhance the quality of patient care, improve patient communications, and better manage the cost of care delivery.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for the full year 2013, and provided a business update.
› Verified 7 days ago
Lars Stangenberg, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2 Dudley St, Suite 470, Providence, RI 02905 Phone: 401-553-8318 Fax: 401-868-2307 | |
Kara Lynne Leonard, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Rih Radiation Oncology, Providence, RI 02903 Phone: 401-444-8311 Fax: 401-444-5335 | |
Michael Low Cardenas, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 825 N Main St, Providence, RI 02904 Phone: 774-279-0884 | |
Earle O Assanah, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5174 | |
Glenn A Tung, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-4000 | |
Sarah-kim Shields, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Radiology, Providence, RI 02903 Phone: 401-444-2133 Fax: 401-444-5017 | |
Sean O'neill, MD Radiology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5127 Fax: 401-444-3056 |